Post-exposure therapy of filovirus infections

Trends in Microbiology

Volumn 22, Issue 8, 2014, Pages 456-463

  Wong, Gary ^a,b   Qiu, Xiangguo ^a   Olinger, Gene G ^c   Kobinger, Gary P ^a,b,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ebola; Filovirus; Immunotherapy; Marburg; Monoclonal antibodies; Post exposure

Indexed keywords

AVI 6002; BCX 4430; DROTRECOGIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13C6; MONOCLONAL ANTIBODY 6D8; MORPHOLINO OLIGONUCLEOTIDE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA INTERFERON; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; VIRUS ANTIBODY;

CONTINUOUS INFUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRIDAE; FILOVIRUS; FILOVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; LLOVIU VIRUS; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MORTALITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIMATE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYMPTOM; THERAPY DELAY; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANIMAL; DISEASE MODEL; FILOVIRIDAE INFECTIONS; POST EXPOSURE PROPHYLAXIS; PROCEDURES; TIME; TREATMENT OUTCOME;

MARBURGVIRUS; PRIMATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; FILOVIRIDAE INFECTIONS; POST-EXPOSURE PROPHYLAXIS; PRIMATES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905114246     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.04.002     Document Type: Review

References (65)

1. Negredo A., et al. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. 2011, 7:e1002304. 10.1371/journal.ppat.1002304.
2. Maruyama J., et al. Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus. J. Virol. 2014, 88:99-109.
3. Nkoghe D., et al. Cutaneous manifestations of filovirus infections. Int. J. Dermatol. 2012, 51:1037-1043.
4. Hartman A.L., et al. Ebola and Marburg hemorrhagic fever. Clin. Lab. Med. 2010, 30:161-177.
5. Fisher-Hoch S.P., et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 1985, 152:887-894.
6. Fisher-Hoch S.P., et al. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 1983, 2:1055-1058.
7. Feldmann H., Geisbert T.W. Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
8. Marburg Virus Disease 1971, Springer. G.A. Martini, R. Siegert (Eds.).
9. Raabea V.N., Borcherta M. Infection control during filoviral hemorrhagic fever outbreaks. J. Glob. Infect. Dis. 2012, 4:69-74.
10. Borchert M., et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect. Dis. 2011, 11:357.
11. Cohen J. Containing the threat - don't forget Ebola. PLoS Med. 2004, 1:e59. 10.1371/journal.pmed.0010059.
12. Johnson E., et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 1995, 76:227-236.
13. Kobinger G.P., et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J. Infect. Dis. 2011, 204:200-208.
14. Weingartl H.M., et al. Transmission of Ebola virus from pigs to non-human primates. Sci. Rep. 2012, 2:811.
15. Clark D.V., et al. Clinical management of filovirus-infected patients. Viruses 2012, 4:1668-1686.
16. Bente D., et al. Disease modeling for Ebola and Marburg viruses. Dis. Model Mech. 2009, 2:12-17.
17. Nakayama E., Saijo M. Animal models for Ebola and Marburg virus infections. Front. Microbiol. 2013, 4:267.
18. Moons A.H., et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb. Haemost. 2002, 88:627-631.
19. Vlasuk G.P., et al. Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant nematode anticoagulant protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. Thromb. Haemost. 2003, 90:803-812.
20. Lee A., et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001, 104:74-78.
21. Moons A.H., et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J. Am. Coll. Cardiol. 2003, 41:2147-2153.
22. Geisbert T.W., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362:1953-1958.
23. Geisbert T.W., et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 2007, 196(Suppl. 2):S372-S381.
24. Hensley L.E., et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007, 196(Suppl. 2):S390-S399.
25. Geisbert T.W., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
26. Warren T.K., et al. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antiviral Res. 2012, 94:80-88.
27. Warren T.K., et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010, 16:991-994.
28. Warren T.K., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014, 10.1038/nature13027.
29. Boudreau J.E., et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 2009, 17:1465-1472.
30. Feldmann H., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007, 3:e2. 10.1371/journal.ppat.0030002.
31. Geisbert T.W., et al. Postexposure treatment of Marburg virus infection. Emerg. Infect. Dis. 2010, 16:1119-1122.
32. Geisbert T.W., et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008, 82:5664-5668.
33. Wilson J.A., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287:1664-1666.
34. Castilho A., et al. Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS ONE 2011, 6:e26040. 10.1371/journal.pone.0026040.
35. Zeitlin L., et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:20690-20694.
36. Olinger G.G., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:18030-18035.
37. Qiu X., et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 2011, 141:218-227.
38. Qiu X., et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis. 2012, 6:e1575. 10.1371/journal.pntd.0001575.
39. Qiu X., et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 2012, 4:138ra181. 10.1126/scitranslmed.3003876.
40. Pettitt J., et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 2013, 5:199ra113. 10.1126/scitranslmed.3006608.
41. Basler C.F., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77:7945-7956.
42. Reid S.P., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80:5156-5167.
43. Wu J.Q., et al. Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 2007, 369:206-213.
44. Richardson J.S., et al. Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J. Bioterror Biodef. 2011, 007:S1. PMID: 23205319, PMCID: PMC3509938.
45. Qiu X., et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J. Virol. 2013, 87:7754-7757.
46. Qiu X., et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci. Transl. Med. 2013, 5:207ra143. 10.1126/scitranslmed.3006605.
47. Jones S.M., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11:786-790.
48. Geisbert T.W., et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008, 4:e1000225. 10.1371/journal.ppat.1000225.
49. Gunther S., et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J. Infect. Dis. 2011, 204(Suppl. 3):S785-S790.
50. Miyoshi K., et al. Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J. Neuropathol. Exp. Neurol. 1971, 30:266-277.
51. Frank A.H., et al. Experimental intracerebral infection of horses, cattle, and sheep with the virus of vesicular stomatitis. Am. J. Vet. Res. 1945, 6:28-38.
52. Olitsky P.K., et al. Comparative studies on the viruses of vesicular stomatitis and equine encephalomyelitis (1). J. Exp. Med. 1934, 59:159-171.
53. Johnson J.E., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
54. Mire C.E., et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012, 6:e1567. 10.1371/journal.pntd.0001567.
55. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 2003, 9:269-277.
56. Reichert J.M., et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
57. Reichert J.M. Which are the antibodies to watch in 2013?. MAbs 2013, 5:1-4.
58. Wong G., et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 2012, 4:158ra146. 10.1126/scitranslmed.3004582.
59. Saijo M., et al. Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin. Vaccine Immunol. 2006, 13:444-451.
60. Mohan G.S., et al. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012, 8:e1003065. 10.1371/journal.ppat.1003065.
61. Wrammert J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
62. Dugdale B., et al. In plant activation: an inducible, hyperexpression platform for recombinant protein production in plants. Plant Cell 2013, 25:2429-2443.
63. Muyembe-Tamfum J.J., et al. Ebola virus outbreaks in Africa: past and present. Onderstepoort J. Vet. Res. 2012, 79:451. 10.4102/ojvr.v79i2.451.
64. Marzi A., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1893-1898.
65. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.